高压氧气治疗对COVID-19后综合征患者心肌功能的影响:随机对照试验
Marina Leitman1,2, Shmuel Fuchs3,4, Vladimir Tyomkin3
1Department of Cardiology, Shamir Medical Center, Zerifin, Israel. marina.leitman@gmail.com.
Scientific reports
|June 10, 2023
概括
高压氧气疗法 (HBOT) 在COVID-19后患者中改善了心脏功能. 这种治疗有助于恢复左心室缩功能,表明长期COVID心脏问题的潜在治疗方法.
科学领域:
- 心脏病学 心脏病学
- 肺部病理学 肺部病理学
- 传染性疾病 传染性疾病
背景情况:
- 后COVID-19条件涉及持续的症状,包括潜在的心脏功能障碍和心血管风险增加.
- 亚临床左心室功能障碍,以减少的全球纵向应变 (GLS) 表示,在COVID-19后的患者中很常见,即使射出分数 (EF) 正常.
研究的目的:
- 评估高压氧气疗法 (HBOT) 在改善COVID-19后心脏功能患者的疗效.
- 评估HBOT对全球纵向菌株 (GLS) 在SARS-CoV-2感染后持续症状的个体的影响.
主要方法:
- 一个随机的,模拟控制的双盲试验,涉及60名患有COVID-19后症状的患者,持续超过三个月.
- 患者每天接受40次HBOT治疗或假药治疗.
- 发声心脏成像在基线和治疗后1-3周进行,以测量心脏功能,特别是GLS.
主要成果:
- 在基线时,48.3%的患者表现出减少的GLS,其中53.3%被分配到HBOT组.
- 在HBOT后,GLS显著改善 (从-17.8±1.1到-20.2±1.0,p=0.0001),与假装组相比,显示出显著的分组时间相互作用 (p=0.041).
- HBOT对左心室缩功能恢复表现出积极影响.
结论:
- 后COVID-19综合征与亚临床左心室功能障碍有关,通常以减少的GLS为特征.
- 高压氧气疗法 (HBOT) 有效地促进左心室缩功能的恢复在COVID-19后病情的患者.
- 需要进一步的研究来优化患者选择,并评估HBOT对COVID-19后心脏功能障碍的长期结果.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
272
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
272
Myocarditis III: Medical Management
9
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
9
Cardiomyopathy III: Hypertrophic Cardiomyopathy
17
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
17
Cardiomyopathy V: Interprofessional Care
18
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
18
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
22
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
22
Acute Coronary Syndrome IV: Interprofessional Care
13
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
13


